Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial (Am J Cardiovasc Drugs, (2016) 16, (139), 10.1007/s40256-015-0156-x);Efficacy and safety study of olmesartan medoxomil, amlodipine, and hydrochlorothiazide combination therapy in patients with hypertension not controlled with olmesartan medoxomil and hydrochlorothiazide combination therapy: Results of a randomized, double-blind, multicenter trial

American Journal of Cardiovascular Drugs

Volumn 16, Issue 2, 2016, Pages 129-138

  Sohn, Il Suk ^a   Kim, Chong Jin ^a   Oh, Byung Hee ^b   Hong, Taek Jong ^c   Park, Chang Gyu ^d   Kim, Byung Soo ^e   Chung, Woo Baek ^f   Nam, Chang Wook ^g   Kim, Cheol Ho ^h   Choi, Dong Ju ^h   Baek, Sang Hong ⁱ   Kim, Woo Shik ^a   Ahn, Tae Hoon ^j   Cho, Jang Hyun ^k   Hwang, Hweung Kon ^l   Shin, Eun Seok ^m   Shin, Joon Han ⁿ   Jeong, Myung Ho ^o   Jeong, Jin Ok ^p   Bae, Jang Ho ^q   Lee, Seung Hwan ^r   Rim, Se Joong ^s   Rhew, Jay Young ^t   Kim, Doo Il ^u   Kim, Dae Kyeong ^u   Kim, Soon Kil ^v   Seo, Hye Sun ^w   Kang, Duk Hyun ^x   Kim, Young Dae ^y   Kim, Dong Woon ^z   Ha, Jong Won ^aa   Park, Woo Jung ^ab   Kim, Tae Ho ^ac   Kim, Kee Sik ^ad   Park, Seung Woo ^ae   Shim, Wan Joo ^af   Yang, Joo Young ^ag   Choi, Jae Woong ^ah   Lee, Sun Hwa ^ai   Ahn, Jeong Cheon ^aj   Lee, Keun ^ak   more..

^a Kyung Hee University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Dae Dong Hospital   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Dongsan Medical Center   (South Korea)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

^j Gachon University   (South Korea)

^k Saint Carollo Hospital   (South Korea)

^l Konkuk University Hospital   (South Korea)

^m University of Ulsan College of Medicine   (South Korea)

ⁿ Ajou University Medical CentSuwon   (South Korea)

^o Chonnam National University Medical School   (South Korea)

^p Chungnam National University College of Medicine   (South Korea)

^q Konyang University   (South Korea)

^r Wonju Severance Christian Hospital   (South Korea)

^s Yonsei University College of Medicine   (South Korea)

^t Presbyterian Medical Center   (South Korea)

^u Inje University   (South Korea)

^v Hanyang University Guri Hospital   (South Korea)

^w Soonchunhyang University College of Medicine   (South Korea)

^x Asan Medical Center   (South Korea)

^y Dong A University   (South Korea)

^z Chungbuk National University Hospital   (South Korea)

^aa Yonsei University College of Medicine   (South Korea)

^ab Hallym University Medical Center   (South Korea)

^ac Chung Ang University College of Medicine   (South Korea)

^ad The National Emergency Medical Center   (South Korea)

^ae Samsung Medical Center   (South Korea)

^af College of Medicine   (South Korea)

^ag National Health Insurance Corporation   (South Korea)

^ah Eulji General Hospital   (South Korea)

^ai Chonbuk National University Medical School   (South Korea)

^aj Korea University   (South Korea)

^ak Seoul Veterans Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEMALE; GENERALIZED EDEMA; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; PRESYNCOPE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TONSILLITIS; TREATMENT RESPONSE; ADVERSE EFFECTS; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; OLMESARTAN MEDOXOMIL; YOUNG ADULT;

EID: 84961214965     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-016-0167-2     Document Type: Erratum

References (19)

1. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1): 3-15. doi: 10.1097/ HJH.0000000000000065.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7): 1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
3. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653): 1114-7. doi: 10.1136/bmj.39553.670231.25.
4. Shin J, Park JB, Kim KI, Kim JH, Yang DH, Pyun WB, et al. 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens. 2015;21(2): 1-13. doi: 10.1186/s40885-014-0014-1.
5. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557): 15. doi: 10.1136/bmj.38875.675486.55.
6. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3): 290-300. doi: 10.1016/j.amjmed.2008.09.038.
7. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2): 399-407. doi: 10.1161/HYPERTENSIONAHA.109.139816.
8. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8): 1296-310.
9. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37(4): 253-390. doi: 10.1038/hr.2014.20.
10. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7): 1252-69. doi: 10.1016/j. clinthera.2010.07.008.
11. Chrysant SG, Littlejohn T 3rd, Izzo JL Jr, Kereiakes DJ, Oparil S, Melino M, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12(4): 233-43. doi: 10.2165/11634160-000000000-00000.
12. Lewin AJ, Izzo JL Jr, Melino M, Lee J, Fernandez V, Heyrman R. Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. Drugs Aging. 2013;30(7): 549-60. doi: 10.1007/s40266-013-0072-1.
13. Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens. 2009;11(9): 475-82. doi: 10. 1111/j.1751-7176.2009.00159.x.
14. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Invest. 2009;29(6): 381-91. doi: 10.2165/00044011-200929060-00002.
15. Lange S, Freitag G. Choice of delta: requirements and reality-results of a systematic review. Biom J. 2005;47(1): 12-27 (discussion 99-107).
16. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7): 1584-90. doi: 10.1097/HJH.0b013e328339f9fa.
17. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5): 875-86. doi: 10.1097/01. hjh.0000059028.82022.89.
18. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311): 995-1003. doi: 10.1016/S0140-6736(02)08089-3.
19. Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7(5): 361-72.